Is Agios Pharm Stock a Good Investment?
Agios Pharm Investment Advice | AGIO |
- Examine Agios Pharm's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Agios Pharm's leadership team and their track record. Good management can help Agios Pharm navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Agios Pharm's business and its evolving consumer preferences.
- Compare Agios Pharm's performance and market position to its competitors. Analyze how Agios Pharm is positioned in terms of product offerings, innovation, and market share.
- Check if Agios Pharm pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Agios Pharm's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Agios Pharm stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Agios Pharm is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Agios Pharm Stock
Researching Agios Pharm's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agios Pharm recorded earning per share (EPS) of 11.64. The entity had not issued any dividends in recent years.
To determine if Agios Pharm is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Agios Pharm's research are outlined below:
| Agios Pharm generated a negative expected return over the last 90 days | |
| Agios Pharm currently holds about 819.31 M in cash with (389.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Auron Therapeutics Expands Leadership with Appointment of Glenn Goddard as Chief Financial Officer |
Agios Pharm uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Agios Pharm. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Agios Pharm's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Agios Pharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Agios Pharm's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2014-03-06 | 2013-12-31 | -0.34 | -0.4 | -0.06 | 17 | ||
2014-08-07 | 2014-06-30 | -0.4 | -0.54 | -0.14 | 35 | ||
2019-08-01 | 2019-06-30 | -1.7 | -1.87 | -0.17 | 10 | ||
2017-02-16 | 2016-12-31 | -1.51 | -1.34 | 0.17 | 11 | ||
2016-05-05 | 2016-03-31 | -0.79 | -0.61 | 0.18 | 22 | ||
2015-02-17 | 2014-12-31 | -0.58 | -0.76 | -0.18 | 31 | ||
2013-11-07 | 2013-09-30 | -0.29 | -0.47 | -0.18 | 62 | ||
2015-11-05 | 2015-09-30 | -0.88 | -1.07 | -0.19 | 21 |
Know Agios Pharm's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Agios Pharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Agios Pharm backward and forwards among themselves. Agios Pharm's institutional investor refers to the entity that pools money to purchase Agios Pharm's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | Bvf Inc | 2024-12-31 | 1.1 M | Jpmorgan Chase & Co | 2024-12-31 | 1 M | Fisher Asset Management, Llc | 2024-12-31 | 960.7 K | Bnp Paribas Investment Partners Sa | 2024-12-31 | 942.2 K | Deutsche Bank Ag | 2024-12-31 | 935.3 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 917.4 K | Gw&k Investment Management, Llc | 2024-12-31 | 683.5 K | Farallon Capital Management, L.l.c. | 2024-12-31 | 5.7 M | Vanguard Group Inc | 2024-12-31 | 5.6 M |
Agios Pharm's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.82 B.Market Cap |
|
Agios Pharm's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.41 | 0.43 | |
| Return On Capital Employed | (0.27) | (0.28) | |
| Return On Assets | 0.41 | 0.43 | |
| Return On Equity | 0.44 | 0.46 |
Determining Agios Pharm's profitability involves analyzing its financial statements and using various financial metrics to determine if Agios Pharm is a good buy. For example, gross profit margin measures Agios Pharm's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Agios Pharm's profitability and make more informed investment decisions.
Evaluate Agios Pharm's management efficiency
Agios Pharm has return on total asset (ROA) of (0.2047) % which means that it has lost $0.2047 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5729 %, meaning that it created $0.5729 on every $100 dollars invested by stockholders. Agios Pharm's management efficiency ratios could be used to measure how well Agios Pharm manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Agios Pharm's Return On Tangible Assets are very stable compared to the past year. As of the 21st of March 2025, Return On Assets is likely to grow to 0.43, while Return On Capital Employed is likely to drop (0.28). At this time, Agios Pharm's Total Assets are very stable compared to the past year. As of the 21st of March 2025, Non Current Assets Total is likely to grow to about 732.5 M, while Other Current Assets are likely to drop about 23.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 27.13 | 28.48 | |
| Tangible Book Value Per Share | 27.13 | 28.48 | |
| Enterprise Value Over EBITDA | (4.34) | (4.56) | |
| Price Book Value Ratio | 1.21 | 1.15 | |
| Enterprise Value Multiple | (4.34) | (4.56) | |
| Price Fair Value | 1.21 | 1.15 | |
| Enterprise Value | 1.8 B | 1.5 B |
The operational strategies employed by Agios Pharm management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.901 |
Basic technical analysis of Agios Stock
As of the 21st of March, Agios Pharm shows the Risk Adjusted Performance of (0.11), mean deviation of 2.33, and Standard Deviation of 3.27. Agios Pharm technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Agios Pharm's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Agios Pharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Agios Pharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Agios Pharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Agios Pharm's Outstanding Corporate Bonds
Agios Pharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Agios Pharm uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Agios bonds can be classified according to their maturity, which is the date when Agios Pharm has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ADVGRO 8625 30 SEP 27 Corp BondUS00840KAA79 | View | |
| US00842XAA72 Corp BondUS00842XAA72 | View | |
| US00846UAL52 Corp BondUS00846UAL52 | View | |
| AGILENT TECHNOLOGIES INC Corp BondUS00846UAK79 | View | |
| AGILENT TECHNOLOGIES INC Corp BondUS00846UAN19 | View | |
| Agilent Technologies 21 Corp BondUS00846UAM36 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View |
Understand Agios Pharm's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Agios Pharm's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 2.33 | |||
| Coefficient Of Variation | (776.92) | |||
| Standard Deviation | 3.27 | |||
| Variance | 10.7 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.15) | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 17.77 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 4.19 | |||
| Skewness | (0.56) | |||
| Kurtosis | 2.63 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 2.33 | |||
| Coefficient Of Variation | (776.92) | |||
| Standard Deviation | 3.27 | |||
| Variance | 10.7 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.39) | |||
| Total Risk Alpha | (0.15) | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 17.77 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 4.19 | |||
| Skewness | (0.56) | |||
| Kurtosis | 2.63 |
Consider Agios Pharm's intraday indicators
Agios Pharm intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Agios Pharm stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Agios Pharm Corporate Filings
F3 | 7th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 5th of March 2025 Other Reports | ViewVerify | |
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Agios Stock media impact
Far too much social signal, news, headlines, and media speculation about Agios Pharm that are available to investors today. That information is available publicly through Agios media outlets and privately through word of mouth or via Agios internal channels. However, regardless of the origin, that massive amount of Agios data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Agios Pharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Agios Pharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Agios Pharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Agios Pharm alpha.
Agios Pharm Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Agios Pharm can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Agios Pharm Historical Investor Sentiment
Investor biases related to Agios Pharm's public news can be used to forecast risks associated with an investment in Agios. The trend in average sentiment can be used to explain how an investor holding Agios can time the market purely based on public headlines and social activities around Agios Pharm. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Agios Pharm's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Agios Pharm and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Agios Pharm news discussions. The higher the estimate score, the more favorable the investor's outlook on Agios Pharm.
Agios Pharm Corporate Management
| DSc FRSC | CoFounder Board | Profile | |
| Dr DACVP | Consultant | Profile | |
| Sarah MD | Chief Development | Profile | |
| James Burns | Corporate Officer | Profile | |
| Ellen LoPrestiv | Chief Officer | Profile | |
| Clive Patience | Chief Officer | Profile | |
| ShinSan Su | CoFounder Board | Profile |
Already Invested in Agios Pharm?
The danger of trading Agios Pharm is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Agios Pharm is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Agios Pharm. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Agios Pharm is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.64 | Revenue Per Share | Quarterly Revenue Growth 0.511 | Return On Assets | Return On Equity |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Agios Pharm's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.